IFM Therapeutics
Latest round
- Series A
Last raised
- Jun 2016
Total raised
- $27M
Investors
- 3
About IFM Therapeutics
Martin Seidel, IFM Therapeutics, LLC operates as a biopharmaceutical company that develops small molecules that modulate novel targets in the innate immune system for cancer, autoimmunity and inflammatory treatment. In March 2024, Novartis International AG acquired IFM Therapeutics, LLC for an initial USD 835 million, with an upfront payment of USD 90 million, and will receive approximately USD 745 million upon achieving milestones through 2024. IFM Therapeutics, LLC developed small molecule drugs that modulate the innate immune system. The company’s portfolio includes NLRP3 antagonists, STING antagonists, and cGAS inhibitors, targeting conditions such as chronic inflammatory and fibrotic disorders, inflammatory bowel disease, neuroinflammation, and cancer. In addition, the firm focuses on improving the lives of patients with inflammation-driven diseases and cancer.
Who invested in IFM Therapeutics
3 investors across 1 round
See all investors in IFM Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jun 22, 2016
Amount
$27M
Investors
Questions about IFM Therapeutics
Who invested in IFM Therapeutics?
IFM Therapeutics has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has IFM Therapeutics raised?
IFM Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did IFM Therapeutics last raise money?
IFM Therapeutics's most recent round on record is a Series A, in Jun 2016.
What does IFM Therapeutics do?
Martin Seidel, IFM Therapeutics, LLC operates as a biopharmaceutical company that develops small molecules that modulate novel targets in the innate immune system for cancer, autoimmunity and inflammatory treatment.
Where is IFM Therapeutics headquartered?
IFM Therapeutics is headquartered in Boston, US.
Which VCs invest in companies like IFM Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at IFM Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like IFM Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.